Compassionate use: access to an unauthorised medicine for a group of patients

Compassionate use makes an unauthorised medicine available to groups of patients with a serious disease who cannot be treated with authorised medicines.

Also known as: compassionate use programme, CUP, expanded access, early access programme

3 min readUpdated

Reviewed by Gosia Luksza, CEO at Regunaut

At a glance

Legal basis
Article 83 of Regulation (EC) No 726/2004
Run by
Member States under national rules; the CHMP can give an opinion
Eligible products
Centralised-scope medicines in clinical trials or under marketing authorisation application
Not the same as
Named-patient supply under Article 5(1) of Directive 2001/83/EC

How it works

Article 83 of Regulation (EC) No 726/2004 allows Member States, by way of exemption from the requirement for a marketing authorisation, to make a medicinal product available for compassionate use. The Regulation defines this as making a product available, for compassionate reasons, to a group of patients with a chronically or seriously debilitating disease, or a disease considered life-threatening, who cannot be treated satisfactorily by an authorised medicinal product. The product must fall within the scope of the centralised procedure and must either be the subject of a marketing authorisation application or be undergoing clinical trials.

Programmes are set up, authorised and supervised nationally, and the rules differ considerably between Member States in who applies, what data are needed, whether the medicine may be charged for and how safety is reported. Article 83 adds an EU layer. A Member State that makes use of the possibility notifies EMA, and the CHMP may adopt an opinion on the conditions for use, the conditions for distribution and the patients targeted. The opinion is not binding, but Member States must take account of it, and EMA publishes the opinions. Such opinions are rare; the CHMP gave one on remdesivir for COVID-19 in April 2020. An opinion does not affect the civil or criminal liability of the manufacturer or the applicant.

Compassionate use is distinct from named-patient supply. Under Article 5(1) of Directive 2001/83/EC, a Member State may exempt a product supplied in response to a bona fide unsolicited order, formulated to the specification of an authorised healthcare professional, for use by an individual patient under that professional's direct personal responsibility. That route covers single patients and any type of product, and EMA is not involved. Neither route is a clinical trial: data collected in a programme cannot replace the trials required for the dossier, although safety information must be collected and reported. Article 83(8) also requires the applicant to make sure that patients in a programme have access to the medicine in the period between authorisation and placing on the market.

What goes wrong

A programme opened in one Member State on the assumption that its approval carries over to others; communication about an unauthorised product that crosses into promotion; supply commitments the company cannot sustain once demand grows; adverse reactions from the programme that never reach the safety database; and no plan for the gap between authorisation and reimbursement, when national programme rules may end while patients still depend on the supply.

Timing

There is no EU timetable. National authorities decide on programmes under their own procedures and deadlines. A CHMP opinion under Article 83 follows notification by a Member State and is updated regularly as new data arrive. A programme normally ends, or is converted under national rules, once the product is authorised and commercially available in the Member State.

Compassionate use: common questions

What is the difference between compassionate use and named-patient supply?

Compassionate use under Article 83 of Regulation (EC) No 726/2004 covers a group of patients and a product that is in clinical trials or under marketing authorisation application. Named-patient supply under Article 5(1) of Directive 2001/83/EC answers a doctor's unsolicited request for one patient under the doctor's direct responsibility. Both are run under national rules, and only the first can involve a CHMP opinion.

Does EMA approve compassionate use programmes?

No. Programmes are authorised and run by the Member States. EMA's role, through the CHMP, is to give an opinion on how the medicine should be used, how it should be distributed and which patients it is for, once a Member State has notified a programme. Member States take the opinion into account but are not bound by it.

Which medicines qualify for compassionate use under Article 83?

Medicines that fall within the scope of the centralised procedure and are either under evaluation in a marketing authorisation application or undergoing clinical trials. The patients must have a chronically or seriously debilitating or life-threatening disease and no satisfactory authorised treatment. Products outside that scope can still be supplied under national schemes.

Sources

  1. EUR-Lex: Regulation (EC) No 726/2004 laying down Union procedures for the authorisation and supervision of medicinal products
  2. European Medicines Agency: Compassionate use
  3. EUR-Lex: Directive 2001/83/EC on the Community code relating to medicinal products for human use

Put your Compassionate use question to Workbench

Workbench answers regulatory questions from EUR-Lex, EMA, national agencies and your own documents, with every claim linked to its source. Start free with welcome credits.